Xuefuzhuyu decoction inhibition of angiogenesis attenuates liver fibrosis induced by CCl4 in mice

Zhou, Ya-Ning; Sun, Mingyu; Mu, Yongping; Yang, Tao; Ning, Bing-Bing; Ren, Shuang; Chen, Jiamei; Liu, Ping

doi:10.1016/j.jep.2014.03.019

Cited by 39 publications

(28 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The increased levels of HIF-1α further stimulates the overexpression of VEGF and VEGFR [47], which in turn promotes endothelium growth and new vessel formation, namely angiogenesis [11]. A recent report has indicated that XFZYD significantly reduces the level of HIF-1α and, as a consequence, VEGF [12]. In addition to the decoction’s antiangiogenic and protective effects, XFZYD would appear to have a potentially important role in preventive medicine, while at the same time providing a relevant and important pharmaceutical effect when one has a familial morbidity or have suffered from previous vision-threatening retinal ischemic disorders such as, wAMD, DR, glaucoma, CRAO, BRAO, CRVO or BRVO.…”

Section: Discussionmentioning

confidence: 99%

“…The study of Lee et al [11] suggested that XFZYD increased the potential of recombinant tissue plasminogen activator (tPA) as a neuroprotection agent against rat brain ischemia. The report of Zhou et al [12] has also indicated that XFZYD seems to be able to alleviate hypoxia and protect liver sinusoidal endothelial cell function and does this by decreasing the levels of VEGF and HIF-1α. The formulation of XFZYD consists of eleven components (with respective representative active compounds in the bracket), namely Radix Angelicae Sinensis (Dang Gui: ferulic acid) [13, 14], Radix Rehmanniae glutinosae (Di Huang: catalpol) [15], Radix Paeoniae Rubra (Chi Shao: peoniflorin) [16], Rhizoma Ligustici Chuanxiong (Chuan Xiong: ferulic acid) [13, 14], Semen Pruni Persicae (Táo Rén: amygdalin) [17], Flos Carthami Tinctorii (Hong Hua: hydroxysafflor yellow A, HSYA) [18], Radix Glycyrrhizae Uralensis (Gan Cao: glycyrrhizin) [19], Fructus Auranti (Zhi Qiao: costunolide) [20], Radix Bupleuri Chinense (Chai Hu: saikosaponin) [21], Radix Achyranthis Bidentatae (Niu Xi: Achyranthes bidentata polysaccharides) [22], and Radix Platycodi Grandiflori (Jie Geng: platycodins) [23].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Xue-fu-Zhu-Yu decoction protects rats against retinal ischemia by downregulation of HIF-1α and VEGF via inhibition of RBP2 and PKM2

Tan

Geng

Liu

et al. 2017

BMC Complement Altern Med

View full text Add to dashboard Cite

BackgroundRetinal ischemia-related eye diseases result in visual dysfunction. This study investigates the protective effects and mechanisms of Xue-Fu-Zhu-Yu decoction (XFZYD) with respect to retinal ischemia.MethodsRetinal ischemia (I) was induced in Wistar rats by a high intraocular pressure (HIOP) of 120 mmHg for 1 h, which was followed by reperfusion of the ischemic eye; the fellow untreated eye acted as a control. Electroretinogram (ERG), biochemistry and histopathology investigations were performed.ResultsSignificant ischemic changes occurred after ischemia including decreased ERG b-wave ratios, less numerous retinal ganglion cells (RGCs), reduced inner retinal thickness, fewer choline acetyltransferase (ChAT) labeled amacrine cell bodies, increased glial fibrillary acidic protein (GFAP) immunoreactivity and increased vimentin Müller immunolabeling. These were accompanied by significant increases in the mRNA/protein concentrations of vascular endothelium growth factor, hypoxia-inducible factor-1α, pyruvate kinase M2 and retinoblastoma-binding protein 2. The ischemic changes were concentration-dependently and significantly altered when XFZYD was given for seven consecutive days before or after retina ischemia, compared to vehicle. These alterations included enhanced ERG b-wave amplitudes, more numerous RGCs, enhanced inner retinal thickness, a greater number of ChAT immunolabeled amacrine cell bodies and decreased GFAP/vimentin immunoreactivity. Furthermore, decreased mRNA levels of VEGF, HIF-1α, PKM2, and RBP2 were also found. Reduced protein concentrations of VEGF, HIF-1α, PKM2, and RBP2 were also demonstrated. Furthermore, there was an inhibition of the ischemia-associated increased ratios (target protein/β-actin) in the protein levels of VEGF, HIF-1α, PKM2, and RBP2, which were induced by Shikonin, JIB-04 or Avastin.ConclusionXFZYD would seem to protect against well-known retinal ischemic changes via a synergistic inhibition of RBP2 and PKM2, as well as down-regulation of HIF-1α and a reduction in VEGF secretion.Electronic supplementary materialThe online version of this article (doi:10.1186/s12906-017-1857-2) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Xue-fu-Zhu-Yu decoction protects rats against retinal ischemia by downregulation of HIF-1α and VEGF via inhibition of RBP2 and PKM2

Tan

Geng

Liu

et al. 2017

BMC Complement Altern Med

View full text Add to dashboard Cite

show abstract

“…As the major component of ECM, type I collagen is composed of HYP [34]. Additionally, HA and LN are important indices to evaluate the collagen extent of hepatic fibrosis [35].…”

Section: Discussionmentioning

confidence: 99%

Astragaloside Alleviates Hepatic Fibrosis Function via PAR2 Signaling Pathway in Diabetic Rats

Wang

Xiang

et al. 2017

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Astragaloside (AGS) extracted from radix astragalin (Huangqi) has been considered to be beneficial to liver diseases. In this study, we examined the role played by AGS in alleviating hepatic fibrosis function via protease-activated receptor-2 (PAR2) mechanisms. We hypothesized that AGS affects PAR2 signaling pathway thereby improving hepatic function in rats with hepatic fibrosis induced by carbon tetrachloride (CCl₄). We further hypothesized that AGS attenuates impaired hepatic function evoked by CCl₄ to a greater degree in diabetic animals. Methods: ELISA and Western Blot analysis were used to examine PAR2 signaling pathway in diabetic CCl₄-rats and non-diabetic CCl₄-rats. Results: AGS inhibited the protein expression of PAR2 and its downstream pathway PKA and PKCɛ in CCl₄-rats. Notably, the effects of AGS were greater in CCl₄-rats with diabetes. AGS also significantly attenuated the CCl₄-induced upregulations of pro-inflammatory cytokines, namely interleukin-1β, interleukin-6 and tumor necrosis factor-α accompanied with decreases of collagenic parameters such as hexadecenoic acid, laminin and hydroxyproline. Additionally, AGS improved the CCl₄-induced exaggerations of liver index and functions including alanine aminotransferase, aspartate aminotransferase. Moreover, TGF-β1, a marker of hepatic fibrosis, was increased in CCl₄-rats and AGS inhibited increases in TGF-β1 induced by CCl₄. Conclusions: AGS alleviates hepatic fibrosis by inhibiting PAR2 signaling expression and its effects are largely enhanced in diabetic animals. Targeting one or more of these signaling molecules may present new opportunities for treatment and management of hepatic fibrosis; and results of our study are likely to shed light on strategies for application of AGS because it has potentially greater therapeutic effectiveness for hepatic fibrosis in diabetes.

show abstract

“…Analysis of serum functional enzymes, including ALT, AST, γ‐GT, and AKP has a vital clinical value in liver function diagnosis (Zhou et al, ). As shown in Figure , DMN treatment increased serum ALT, AST, γ‐GT, and AKP activities compared with those of the control group ( P < 0.01).…”

Section: Resultsmentioning

confidence: 99%

Herbal Formula, Baogan Yihao (BGYH), Prevented Dimethylnitrosamine(DMN)‐Induced Liver Injury in Rats

Liu

Shi

et al. 2017

Drug Development Research

View full text Add to dashboard Cite

Preclinical Research Baogan Yihao (BGYH) is a traditional Chinese herbal medicine for the treatment of chronic liver diseases. In this study, the effects of BGYH on dimethylnitrosamine (DMN)-induced liver fibrosis were investigated using a rat model. BGYH alleviate liver damage, as indicated by decreased levels of AST, ALT, γ-GT, and AKP. BGYH also prevented collagen deposition and reduced pathological tissue injury in liver tissue. In fibrosis, high levels of α-SMA and TGF-β in liver tissue were markedly attenuated by BGYH. The inhibitory effect of BGYH on HSC-T6 proliferation demonstrated that BGYH exhibited significant hepatoprotective and antifibrogenic effects on DMN-induced liver injury. These findings suggest that BGYH may have therapeutic potential in the prevention and therapy of liver fibrosis. Drug Dev Res 78 : 155-163, 2017. © 2017 Wiley Periodicals, Inc.

show abstract

Xuefuzhuyu decoction inhibition of angiogenesis attenuates liver fibrosis induced by CCl4 in mice

Cited by 39 publications

References 18 publications

Xue-fu-Zhu-Yu decoction protects rats against retinal ischemia by downregulation of HIF-1α and VEGF via inhibition of RBP2 and PKM2

Xue-fu-Zhu-Yu decoction protects rats against retinal ischemia by downregulation of HIF-1α and VEGF via inhibition of RBP2 and PKM2

Astragaloside Alleviates Hepatic Fibrosis Function via PAR2 Signaling Pathway in Diabetic Rats

Herbal Formula, Baogan Yihao (BGYH), Prevented Dimethylnitrosamine(DMN)‐Induced Liver Injury in Rats

Contact Info

Product

Resources

About